Formulation of Antiacne Gel Using 1,5-Bis(3’-Etoksi-4’-Hidroksifenil)-1,4-Pentadien-3-On (EHP) As Antibacterial Agent

  • Esti Mulatsari Universitas Pancasila
  • Esti Mumpuni
  • Agus Purwanggana
  • Siti Marsha Dyah Kusumaningtyas
DOI: https://doi.org/10.35814/jifi.v19i2.1085

Abstract

Acne is a skin disease that causes non-inflammatory follicular papules, nodules, pustules and inflammatory papules. There are various oral and topical anti-acne preparations on the market. Gels are topical preparations that have better absorption than cream preparations. The anti-acne gel is formulated with antibacterial active compounds. The compound 1,5-bis(3’-ethoxy-4’-hydroxyphenyl)-1,4-pentadien-3-one (EHP) is one of the curcumin analogue compounds that have been successfully synthesized by Mumpuni et al, 2010. EHP has the potential to inhibit growth of pathogenic microbes such as Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli and Salmonella typhi, and has anti-inflammatory activity. This study aims to make an anti-acne gel formula with the active ingredient EHP as an antimicrobial agent. The formula was tested for physical and chemical stability including organoleptic, spreadability, homogeneity, viscosity, flow properties, microbiological activity and skin irritation ability. EHP is formulated in gel preparations in various concentrations. Stability test of gel preparations was carried out at a temperature of 40 °C; RH ± 75% for 4 weeks.The results showed that EHP can be formulated into gel preparations that meet the physical and chemical quality requirements. Gel preparations with the active ingredient EHP 0.1%; tretionine 0.01%; carbopol 940 1.0%; triethanolamine 1.0%; propylenglycol 15%; ethanol (96%) 10%; can inhibit the Propionibacterium acnes bacteria with a diameter of 19.6 mm in the inhibition area, the skin irritation test of rabbits does not cause irritation, thus the gel preparation with the active ingredient EHP is suitable to be developed as an anti-acne gel product.

References

1. David SP. Anatomi fisiologi kulit dan penyembuhan luka. Surabaya: Universitas Airlangga; 2007. h 1-8.

2. Diah SS, Darusman LK, Triwahyuni W. Efektivitas krim anti jerawat kayu secang Caesalpinia sappan
terhadap Propionibacterium acnes pada kulit kelinci. 2013; 11(2): 175–81.

3. Dhillon KS, Varshney KR. Study of microbiological spectrum in Acne vulgaris: an in vitro study. Scholars
Journal of Applied Medical Science. 2013 ; 1 (6): 724-727.

4. Lindsay J. Staphylococcus: molecular genetics, Inggris: Caister Aca Pr; 2008 ; h 165-173.

5. Atmaja, WSM. Penuntun ilmu kosmetik medik. 1997; Jakarta: UI Press.

6. Ansel, H.C. Pengantar bentuk sediaan farmasi. Edisi keempat. Jakarta. UI Press. 2005 ; h: 217-218.

7. Wyatt EL, Sutter SH, Drake LA. Dermatological pharmacology, Hardman, JG, Limbird IE, Goodman
and Gillman’s the pharmacological basis of therapeutic, 10th ed., 2001 ;1795-814, McGraw Hill, New York.

8. Abbasi MA, Kusar A, Rehman A, Saleem H, Jahangir SM, Zahra S. Preparation of new formulation of
antiacne cream and their effi cacy. African Journal of Pharmacy and Pharmacology. 2010 ; Vol.4(6); 298-303.
ISSN 1996-0816.

9. Purwati V. Uji Aktivitas Antibakteri Penyebab Jerawat Dari Daun Dewa. Padang: Fakultas Farmasi
Universitas Andalas. 2010 ; h. 92-93.

10. 10. Kumesan YAN, Yamlean PVY, Supriati HS, Studi P, Unsrat F. Formulasi dan uji aktivitas gel antijerawat
ekstrak umbi bakung (Crinum asiaticum L .) terhadap bakteri Staphylococcus aureus secara in vitro. 2013;
2(2):18–27.

11. Sari, R., Nurbaeti, S.N., Pratiwi, L., Optimasi kombinasi karbopol 940 dan HPMC terhadap sifat fi sik
gel ekstrak dan fraksi metanol daun kesum (Polygonum minus Huds.) dengan metode simplex lattice design.
Pharmaceutical Sciences and Research. 2016 ; 3(2), 72-79.

12. Mumpuni E, Indriana P, Sulastri E, Rusnawan E. Sintesis dan uji antioksidan senyawa 1,5-bis(3’etoksi-
4’-hidroksifenil)-1,4-pentadien-3-on (EHP). JIFI.; 2010 ; 8(2):93-102.

13. Mumpuni E. Sintesis organik gelombang mikro senyawa 1,5-Bis(3’-Etoksi-4’-Hidroksifenil)-1,4-
Pentadien-3-on (EHP) dan Uji In Silico Inhibisi COX-2 serta uji aktifitas farmakologi. 2016; (April): 4–5.

14. Mumpuni E, Agus N, Andarini M, Sudarmanto A. The molecular docking of 1,5-diphenil-1,4-pentadien-3-on
derivates as the inhibitor of COX-2 enzyme. Dalam: Henk Timmerman International Seminar & Awards
(HTSIA) on Structure Based Drug Design. Yogyakarta; Oktober 7th, .2009.

15. Koriyanti U. Reproduksi 1,5-bis (3’etoksi-4’ hidroksifenil)-1,4 pent adien-3-on (EHP) dan
Potensinya Sebagai Antibakteri.(skripsi). Jakarta: Fakultas Farmasi Universitas Pancasila. 2016.

16. Purwanggana A, Mumpuni E, Mulatsari E. In vitro and in silico antibacterial activity of 1.5-bis (3’-ethoxy-
4’-hydroxyphenyl)-1-4-pentadiene-3-one. Int J Phar
Pharm Sci. 2018 ; 10(5).

17. Peraturan Kepala Badan Pengawas Obat dan Makanan Republik Indonesia Nomor 7 Tahun 2014 tentang
Pedoman uji toksisitas non klinik secara in vivo.
Published
2021-10-31
How to Cite
MULATSARI, Esti et al. Formulation of Antiacne Gel Using 1,5-Bis(3’-Etoksi-4’-Hidroksifenil)-1,4-Pentadien-3-On (EHP) As Antibacterial Agent. JURNAL ILMU KEFARMASIAN INDONESIA, [S.l.], v. 19, n. 2, p. 216-225, oct. 2021. ISSN 2614-6495. Available at: <http://jifi.farmasi.univpancasila.ac.id/index.php/jifi/article/view/1085>. Date accessed: 18 apr. 2024. doi: https://doi.org/10.35814/jifi.v19i2.1085.
Citation Formats
Issue
Vol 19 No 2 (2021): JIFI
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

Licencing
All articles in Jurnal Ilmu Kefarmasian Indonesia are an open-access article, distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted non-commercial used, distribution and reproduction in any medium.

This licence applies to Author(s) and Public Reader means that the users mays :

  • SHARE:
    copy and redistribute the article in any medium or format
  • ADAPT:
    remix, transform, and build upon the article (eg.: to produce a new research work and, possibly, a new publication)
  • ALIKE:
    If you remix, transform, or build upon the article, you must distribute your contributions under the same license as the original.
  • NO ADDITIONAL RESTRICTIONS:
    You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

It does however mean that when you use it you must:

  • ATTRIBUTION: You must give appropriate credit to both the Author(s) and the journal, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

You may not:

  • NONCOMMERCIAL: You may not use the article for commercial purposes.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.